Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Carvedilol
All strengths: Limited Use, Reason for Use code 183 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 183 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Auro-Carvedilol · DIN 02418495 · 3.125 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418495
Manufacturer: Auro Pharma Inc.; listing date 2014-04-30
Daily cost (source): $0.4120
Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418495)
Source record
DIN 02418495: Auro-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id AUR
Source form: Tab; strength: 3.125mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418495
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90306
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060
Carvedilol · DIN 02248752 · $0.2060
Carvedilol · DIN 02364913 · $0.2060
Coreg · DIN 02229650 · not recorded
Jamp-Carvedilol · DIN 02368897 · $0.2060
PMS-Carvedilol · DIN 02245914 · $0.2060
Ran-Carvedilol · DIN 02268027 · $0.2060
Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended September 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02418495
Shortage record checked October 6, 2026
Carvedilol · DIN 02248752 · 3.125 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248752
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-10-24 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248752)
Source record
DIN 02248752: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id SIV
Source form: Tab; strength: 3.125mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248752
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73120
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060
Auro-Carvedilol · DIN 02418495 · $0.2060
Carvedilol · DIN 02364913 · $0.2060
Coreg · DIN 02229650 · not recorded
Jamp-Carvedilol · DIN 02368897 · $0.2060
PMS-Carvedilol · DIN 02245914 · $0.2060
Ran-Carvedilol · DIN 02268027 · $0.2060
Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended May 20, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248752
Shortage record checked October 6, 2026
Carvedilol · DIN 02364913 · 3.125 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364913
Manufacturer: Sanis Health Inc.; listing date 2011-10-25
Daily cost (source): $0.4120
Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364913)
Source record
DIN 02364913: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id SAI
Source form: Tab; strength: 3.125mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364913
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84979
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060
Auro-Carvedilol · DIN 02418495 · $0.2060
Carvedilol · DIN 02248752 · $0.2060
Coreg · DIN 02229650 · not recorded
Jamp-Carvedilol · DIN 02368897 · $0.2060
PMS-Carvedilol · DIN 02245914 · $0.2060
Ran-Carvedilol · DIN 02268027 · $0.2060
Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended November 25, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364913
Shortage record checked October 6, 2026
Jamp-Carvedilol · DIN 02368897 · 3.125 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368897
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Daily cost (source): $0.4120
Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368897)
Source record
DIN 02368897: Jamp-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id JPC
Source form: Tab; strength: 3.125mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368897
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85386
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060
Auro-Carvedilol · DIN 02418495 · $0.2060
Carvedilol · DIN 02248752 · $0.2060
Carvedilol · DIN 02364913 · $0.2060
Coreg · DIN 02229650 · not recorded
PMS-Carvedilol · DIN 02245914 · $0.2060
Ran-Carvedilol · DIN 02268027 · $0.2060
Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended August 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368897
Shortage record checked October 6, 2026
PMS-Carvedilol · DIN 02245914 · 3.125 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245914
Manufacturer: Pharmascience Inc.; listing date 2004-04-06
Daily cost (source): $0.4120
Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245914)
Source record
DIN 02245914: PMS-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id PMS
Source form: Tab; strength: 3.125mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245914
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70034
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060
Auro-Carvedilol · DIN 02418495 · $0.2060
Carvedilol · DIN 02248752 · $0.2060
Carvedilol · DIN 02364913 · $0.2060
Coreg · DIN 02229650 · not recorded
Jamp-Carvedilol · DIN 02368897 · $0.2060
Ran-Carvedilol · DIN 02268027 · $0.2060
Ratio-Carvedilol · DIN 02252309 · $0.2060
Shortage status: resolved shortage (ended June 26, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245914
Shortage record checked October 6, 2026
Ratio-Carvedilol · DIN 02252309 · 3.125 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252309
Manufacturer: Ratiopharm Inc.; listing date 2004-07-20
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 3.125 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRatio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252309)
Source record
DIN 02252309: Ratio-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400140; group id 278; item number 0576; lccId 00050; manufacturer id RPH
Source form: Tab; strength: 3.125mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252309
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73718
Interchangeable products
Apo-Carvedilol · DIN 02247933 · $0.2060
Auro-Carvedilol · DIN 02418495 · $0.2060
Carvedilol · DIN 02248752 · $0.2060
Carvedilol · DIN 02364913 · $0.2060
Coreg · DIN 02229650 · not recorded
Jamp-Carvedilol · DIN 02368897 · $0.2060
PMS-Carvedilol · DIN 02245914 · $0.2060
Ran-Carvedilol · DIN 02268027 · $0.2060
Shortage status: resolved shortage (ended May 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252309
Shortage record checked October 6, 2026
Auro-Carvedilol · DIN 02418509 · 6.25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418509
Manufacturer: Auro Pharma Inc.; listing date 2014-04-30
Daily cost (source): $0.4120
Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418509)
Source record
DIN 02418509: Auro-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id AUR
Source form: Tab; strength: 6.25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418509
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90307
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060
Carvedilol · DIN 02248753 · $0.2060
Carvedilol · DIN 02364921 · $0.2060
Coreg · DIN 02229651 · not recorded
Jamp-Carvedilol · DIN 02368900 · $0.2060
PMS-Carvedilol · DIN 02245915 · $0.2060
Ran-Carvedilol · DIN 02268035 · $0.2060
Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended March 29, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02418509
Shortage record checked October 6, 2026
Carvedilol · DIN 02248753 · 6.25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248753
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-07-06 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248753)
Source record
DIN 02248753: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id SIV
Source form: Tab; strength: 6.25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248753
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73121
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060
Auro-Carvedilol · DIN 02418509 · $0.2060
Carvedilol · DIN 02364921 · $0.2060
Coreg · DIN 02229651 · not recorded
Jamp-Carvedilol · DIN 02368900 · $0.2060
PMS-Carvedilol · DIN 02245915 · $0.2060
Ran-Carvedilol · DIN 02268035 · $0.2060
Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended September 3, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248753
Shortage record checked October 6, 2026
Carvedilol · DIN 02364921 · 6.25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364921
Manufacturer: Sanis Health Inc.; listing date 2011-10-25
Daily cost (source): $0.4120
Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364921)
Source record
DIN 02364921: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id SAI
Source form: Tab; strength: 6.25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364921
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84980
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060
Auro-Carvedilol · DIN 02418509 · $0.2060
Carvedilol · DIN 02248753 · $0.2060
Coreg · DIN 02229651 · not recorded
Jamp-Carvedilol · DIN 02368900 · $0.2060
PMS-Carvedilol · DIN 02245915 · $0.2060
Ran-Carvedilol · DIN 02268035 · $0.2060
Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended August 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364921
Shortage record checked October 6, 2026
Jamp-Carvedilol · DIN 02368900 · 6.25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368900
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Daily cost (source): $0.4120
Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368900)
Source record
DIN 02368900: Jamp-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id JPC
Source form: Tab; strength: 6.25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368900
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85387
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060
Auro-Carvedilol · DIN 02418509 · $0.2060
Carvedilol · DIN 02248753 · $0.2060
Carvedilol · DIN 02364921 · $0.2060
Coreg · DIN 02229651 · not recorded
PMS-Carvedilol · DIN 02245915 · $0.2060
Ran-Carvedilol · DIN 02268035 · $0.2060
Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended March 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368900
Shortage record checked October 6, 2026
PMS-Carvedilol · DIN 02245915 · 6.25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245915
Manufacturer: Pharmascience Inc.; listing date 2004-04-06
Daily cost (source): $0.4120
Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245915)
Source record
DIN 02245915: PMS-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id PMS
Source form: Tab; strength: 6.25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245915
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70035
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060
Auro-Carvedilol · DIN 02418509 · $0.2060
Carvedilol · DIN 02248753 · $0.2060
Carvedilol · DIN 02364921 · $0.2060
Coreg · DIN 02229651 · not recorded
Jamp-Carvedilol · DIN 02368900 · $0.2060
Ran-Carvedilol · DIN 02268035 · $0.2060
Ratio-Carvedilol · DIN 02252317 · $0.2060
Shortage status: resolved shortage (ended June 26, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245915
Shortage record checked October 6, 2026
Ratio-Carvedilol · DIN 02252317 · 6.25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252317
Manufacturer: Ratiopharm Inc.; listing date 2004-07-20
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 6.25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRatio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252317)
Source record
DIN 02252317: Ratio-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400141; group id 278; item number 0577; lccId 00050; manufacturer id RPH
Source form: Tab; strength: 6.25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252317
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73719
Interchangeable products
Apo-Carvedilol · DIN 02247934 · $0.2060
Auro-Carvedilol · DIN 02418509 · $0.2060
Carvedilol · DIN 02248753 · $0.2060
Carvedilol · DIN 02364921 · $0.2060
Coreg · DIN 02229651 · not recorded
Jamp-Carvedilol · DIN 02368900 · $0.2060
PMS-Carvedilol · DIN 02245915 · $0.2060
Ran-Carvedilol · DIN 02268035 · $0.2060
Shortage status: resolved shortage (ended May 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252317
Shortage record checked October 6, 2026
Auro-Carvedilol · DIN 02418517 · 12.5 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418517
Manufacturer: Auro Pharma Inc.; listing date 2014-04-30
Daily cost (source): $0.4120
Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418517)
Source record
DIN 02418517: Auro-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id AUR
Source form: Tab; strength: 12.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418517
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90308
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060
Carvedilol · DIN 02248754 · $0.2060
Carvedilol · DIN 02364948 · $0.2060
Coreg · DIN 02229652 · not recorded
Jamp-Carvedilol · DIN 02368919 · $0.2060
PMS-Carvedilol · DIN 02245916 · $0.2060
Ran-Carvedilol · DIN 02268043 · $0.2060
Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended October 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02418517
Shortage record checked October 6, 2026
Carvedilol · DIN 02248754 · 12.5 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248754
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-07-06 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248754)
Source record
DIN 02248754: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id SIV
Source form: Tab; strength: 12.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248754
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73122
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060
Auro-Carvedilol · DIN 02418517 · $0.2060
Carvedilol · DIN 02364948 · $0.2060
Coreg · DIN 02229652 · not recorded
Jamp-Carvedilol · DIN 02368919 · $0.2060
PMS-Carvedilol · DIN 02245916 · $0.2060
Ran-Carvedilol · DIN 02268043 · $0.2060
Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended August 12, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248754
Shortage record checked October 6, 2026
Carvedilol · DIN 02364948 · 12.5 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364948
Manufacturer: Sanis Health Inc.; listing date 2011-10-25
Daily cost (source): $0.4120
Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364948)
Source record
DIN 02364948: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id SAI
Source form: Tab; strength: 12.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364948
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84981
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060
Auro-Carvedilol · DIN 02418517 · $0.2060
Carvedilol · DIN 02248754 · $0.2060
Coreg · DIN 02229652 · not recorded
Jamp-Carvedilol · DIN 02368919 · $0.2060
PMS-Carvedilol · DIN 02245916 · $0.2060
Ran-Carvedilol · DIN 02268043 · $0.2060
Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended April 22, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364948
Shortage record checked October 6, 2026
Jamp-Carvedilol · DIN 02368919 · 12.5 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368919
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Daily cost (source): $0.4120
Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368919)
Source record
DIN 02368919: Jamp-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id JPC
Source form: Tab; strength: 12.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368919
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85388
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060
Auro-Carvedilol · DIN 02418517 · $0.2060
Carvedilol · DIN 02248754 · $0.2060
Carvedilol · DIN 02364948 · $0.2060
Coreg · DIN 02229652 · not recorded
PMS-Carvedilol · DIN 02245916 · $0.2060
Ran-Carvedilol · DIN 02268043 · $0.2060
Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended July 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368919
Shortage record checked October 6, 2026
PMS-Carvedilol · DIN 02245916 · 12.5 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245916
Manufacturer: Pharmascience Inc.; listing date 2004-04-06
Daily cost (source): $0.4120
Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245916)
Source record
DIN 02245916: PMS-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id PMS
Source form: Tab; strength: 12.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245916
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70036
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060
Auro-Carvedilol · DIN 02418517 · $0.2060
Carvedilol · DIN 02248754 · $0.2060
Carvedilol · DIN 02364948 · $0.2060
Coreg · DIN 02229652 · not recorded
Jamp-Carvedilol · DIN 02368919 · $0.2060
Ran-Carvedilol · DIN 02268043 · $0.2060
Ratio-Carvedilol · DIN 02252325 · $0.2060
Shortage status: resolved shortage (ended July 12, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245916
Shortage record checked October 6, 2026
Ratio-Carvedilol · DIN 02252325 · 12.5 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252325
Manufacturer: Ratiopharm Inc.; listing date 2004-07-20
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 12.5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRatio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252325)
Source record
DIN 02252325: Ratio-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400142; group id 278; item number 0578; lccId 00050; manufacturer id RPH
Source form: Tab; strength: 12.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252325
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73720
Interchangeable products
Apo-Carvedilol · DIN 02247935 · $0.2060
Auro-Carvedilol · DIN 02418517 · $0.2060
Carvedilol · DIN 02248754 · $0.2060
Carvedilol · DIN 02364948 · $0.2060
Coreg · DIN 02229652 · not recorded
Jamp-Carvedilol · DIN 02368919 · $0.2060
PMS-Carvedilol · DIN 02245916 · $0.2060
Ran-Carvedilol · DIN 02268043 · $0.2060
Shortage status: resolved shortage (ended May 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252325
Shortage record checked October 6, 2026
Auro-Carvedilol · DIN 02418525 · 25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Carvedilol · DIN 02418525
Manufacturer: Auro Pharma Inc.; listing date 2014-04-30
Daily cost (source): $0.4120
Health Canada: Marketed since 2014-02-06 · brand AURO-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02418525)
Source record
DIN 02418525: Auro-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id AUR
Source form: Tab; strength: 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02418525
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90309
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060
Carvedilol · DIN 02248755 · $0.2060
Carvedilol · DIN 02364956 · $0.2060
Coreg · DIN 02229653 · not recorded
Jamp-Carvedilol · DIN 02368927 · $0.2060
PMS-Carvedilol · DIN 02245917 · $0.2060
Ran-Carvedilol · DIN 02268051 · $0.2060
Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended October 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02418525
Shortage record checked October 6, 2026
Carvedilol · DIN 02248755 · 25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02248755
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-03-02
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-07-06 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248755)
Source record
DIN 02248755: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id SIV
Source form: Tab; strength: 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248755
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73123
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060
Auro-Carvedilol · DIN 02418525 · $0.2060
Carvedilol · DIN 02364956 · $0.2060
Coreg · DIN 02229653 · not recorded
Jamp-Carvedilol · DIN 02368927 · $0.2060
PMS-Carvedilol · DIN 02245917 · $0.2060
Ran-Carvedilol · DIN 02268051 · $0.2060
Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended September 3, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248755
Shortage record checked October 6, 2026
Carvedilol · DIN 02364956 · 25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Carvedilol · DIN 02364956
Manufacturer: Sanis Health Inc.; listing date 2011-10-25
Daily cost (source): $0.4120
Health Canada: Marketed since 2013-10-12 · brand CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCarvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364956)
Source record
DIN 02364956: Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id SAI
Source form: Tab; strength: 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364956
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84982
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060
Auro-Carvedilol · DIN 02418525 · $0.2060
Carvedilol · DIN 02248755 · $0.2060
Coreg · DIN 02229653 · not recorded
Jamp-Carvedilol · DIN 02368927 · $0.2060
PMS-Carvedilol · DIN 02245917 · $0.2060
Ran-Carvedilol · DIN 02268051 · $0.2060
Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364956
Shortage record checked October 6, 2026
Jamp-Carvedilol · DIN 02368927 · 25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Jamp-Carvedilol · DIN 02368927
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Daily cost (source): $0.4120
Health Canada: Marketed since 2022-01-12 · brand JAMP-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368927)
Source record
DIN 02368927: Jamp-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id JPC
Source form: Tab; strength: 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368927
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85389
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060
Auro-Carvedilol · DIN 02418525 · $0.2060
Carvedilol · DIN 02248755 · $0.2060
Carvedilol · DIN 02364956 · $0.2060
Coreg · DIN 02229653 · not recorded
PMS-Carvedilol · DIN 02245917 · $0.2060
Ran-Carvedilol · DIN 02268051 · $0.2060
Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended July 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368927
Shortage record checked October 6, 2026
PMS-Carvedilol · DIN 02245917 · 25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Carvedilol · DIN 02245917
Manufacturer: Pharmascience Inc.; listing date 2004-04-06
Daily cost (source): $0.4120
Health Canada: Marketed since 2003-08-04 · brand PMS-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245917)
Source record
DIN 02245917: PMS-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id PMS
Source form: Tab; strength: 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245917
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70037
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060
Auro-Carvedilol · DIN 02418525 · $0.2060
Carvedilol · DIN 02248755 · $0.2060
Carvedilol · DIN 02364956 · $0.2060
Coreg · DIN 02229653 · not recorded
Jamp-Carvedilol · DIN 02368927 · $0.2060
Ran-Carvedilol · DIN 02268051 · $0.2060
Ratio-Carvedilol · DIN 02252333 · $0.2060
Shortage status: resolved shortage (ended September 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245917
Shortage record checked October 6, 2026
Ratio-Carvedilol · DIN 02252333 · 25 mg · tablet
Limited Use, Reason for Use code 183 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 183 (criteria below)
Ontario Limited Use criteria, code 183
Coverage limit:
For patients with:
Reason for Use code 183
a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Carvedilol · DIN 02252333
Manufacturer: Ratiopharm Inc.; listing date 2004-07-20
Daily cost (source): $0.4120
Health Canada: Marketed since 2018-01-09 · brand TEVA-CARVEDILOL · ATC C07AG02 CARVEDILOL · form Tablet · route Oral · ingredients CARVEDILOL 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRatio-Carvedilol: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2060). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02252333)
Source record
DIN 02252333: Ratio-Carvedilol
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400143; group id 278; item number 0579; lccId 00050; manufacturer id RPH
Source form: Tab; strength: 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2060; ministry $0.2060
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02252333
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73721
Interchangeable products
Apo-Carvedilol · DIN 02247936 · $0.2060
Auro-Carvedilol · DIN 02418525 · $0.2060
Carvedilol · DIN 02248755 · $0.2060
Carvedilol · DIN 02364956 · $0.2060
Coreg · DIN 02229653 · not recorded
Jamp-Carvedilol · DIN 02368927 · $0.2060
PMS-Carvedilol · DIN 02245917 · $0.2060
Ran-Carvedilol · DIN 02268051 · $0.2060
Shortage status: resolved shortage (ended October 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252333
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C07A): coverage varies; not interchangeable
- Acebutolol (Sectral): general benefit, not a benefit
- Atenolol (Apo-Atenol): general benefit
- Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, not a benefit
- Metoprolol (Lopresor SR): general benefit, not a benefit
- Nadolol (Corgard): general benefit, not a benefit
- Propranolol (Inderal-LA): general benefit, not a benefit
3 more in the class list below
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered
Matched class: 24:04 Cardiac Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL
Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL
24:00 CARDIOVASCULAR DRUGS
· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00
24:04 Cardiac Drugs
· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab
· 26 products · General benefit · strengths: 50mg, 100mg · Tab
· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab
· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab
· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab
· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab
· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab
· 59 products ·
Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:04
and 9 more
Full class listing
Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.